Advanced search×

Gene therapy for haemophilia.

K J KJ Pasi

Baillieres Clin Haematol 9(2):305-17 (1996) PMID 8800507

DOI: 10.1016/S0950-3536(96)80065-5
Version: za2963e q8za6 q8zb1 q8zc4 q8zd0 q8ze5 q8zf0 q8zg2
Buy PDF

Similar articles you may find interesting…

  1. Challenges of rare disease research: limited patients and competing priorities.
    M V MV Ragni, C G CG Moore, and

    Haemophilia 18(3):e192-4 (2012) PMID 21910791

    We achieve in this ongoing process will hopefully not only enable clinical trials research in a rare disease, but also in many medical genetic disease of the future....
    Buy PDF
  2. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven^(R)) therapy in haemophilia a patients
    Dorthe Viuff, Søren Andersen, and Stefan Lethagen

    Thromb Res Suppl 126(2):6 (2010) PMID 20542542

    There is no established laboratory method that can predict the most optimal dose of bypassing agents for treatment of haemophilia A. The objectives of the study was to develop an assay that can a) differentiate between the haemostatic capacity in blood from healthy individuals and se...
    Buy PDF
  3. Special lectures in haemophilia management.
    A A Batorova, K A KA High, and A A Gringeri

    Haemophilia (2010) PMID 20590852

    SUMMARY: During the last two decades major advances have been achieved in the management of haemophilia. Modern approaches aimed at preventing the recurrent bleedings and their sequelae have been widely adopted. Major challenges of intensive treatment regimens employed today, such a short half life...
    Buy PDF